Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

DS takes more inspiration from Bentley than Audi, according to design chief Thierry Metroz. Stellantis’ DS brand plans to go “beyond premium” as it aims to break into the luxury segment. It ...

BRUSSELS, Jan 21 (Reuters) - U.S.-based International Paper (IP.N), opens new tab is set to get EU approval for its 5.8 billion pound ($7.12 billion) purchase of UK rival DS Smith (SMDS.L), opens ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...

Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as H5N1, that are seen as potential pandemic risks. Announced Friday as ...

But Datroway’s results come up short compared with Enhertu. The Citeline report also noted one treatment-related death in the Datroway trial. Given that patients with advanced breast cancer have ...

Enhertu is indicated for the treatment of adult patients with ... during or within six months of completing adjuvant chemotherapy. Trastuzumab deruxtecan (DS-8201) is under development for the ...

Enhertu. The approval is the first in the U.S. for Datroway, which got clearance in Japan last month. Astra and Daiichi withdrew an application in the European Union for the drug to treat a type ...

There’s a meaty LFO section with 14 waveforms, two wave selectors, seven routing switches and five depth attenuverters, while the CPM DS-2 sports a total of 12 modular patch points. Effects include ...

Enhertu is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the ...